T.RowePrice®



SEMIANNUAL REPORT

June 30, 2023

T. ROWE PRICE

Blue Chip Growth Portfolio

For more insights from T. Rowe Price investment professionals, go to **troweprice.com**.

Go Paperless

Sign up for e-delivery of your statements, confirmations, and prospectuses or shareholder reports.

(→) TO ENROLL:

If you invest directly with T. Rowe Price, go to **troweprice.com/paperless**.

If you invest through an investment advisor, a bank, or a brokerage firm, please contact that organization and ask if it can provide electronic documentation. **It's fast**—receive your statements and confirmations faster than U.S. mail.

It's convenient—access your important account documents whenever you need them.

It's secure—we protect your online accounts using "True Identity" to confirm new accounts and make verification faster and more secure.

It can save you money—where applicable, T. Rowe Price passes on the cost savings to fund holders.*

Log in to your account at **troweprice.com** for more information.

* Certain mutual fund accounts that are assessed an annual account service fee can also save money by switching to e-delivery.

Market Commentary

Dear Investor

Most major global stock and bond indexes produced positive returns during the first half of your fund's fiscal year, the sixmonth period ended June 30, 2023. Despite turmoil in the banking sector and a protracted debt ceiling standoff, markets were resilient as growth remained positive in the major economies and corporate earnings results came in stronger than expected.

For the six-month period, the technology-oriented Nasdaq Composite Index gained more than 30%, the strongest result of the major benchmarks, as tech companies benefited from investor enthusiasm for artificial intelligence applications. Growth stocks outperformed value shares, and developed market stocks generally outpaced their emerging market counterparts. Currency movements were mixed over the period, although a weaker dollar versus major European currencies was beneficial for U.S. investors in European securities.

Within the S&P 500 Index, the information technology, communication services, and consumer discretionary sectors were all lifted by the tech rally and recorded significant gains. Conversely, the defensive utilities sector had the weakest returns in the growth-focused environment, and the energy sector also lost ground amid declining oil prices. The financials sector partly recovered from the failure of three large regional banks during the period but still finished with modest losses.

Cheaper oil contributed to slowing inflation, although core inflation readings—which exclude volatile food and energy prices—remained stubbornly high. In response, the Federal Reserve raised its short-term lending benchmark rate to a target range of 5.00% to 5.25% by early May, the highest level since 2007. The Fed held rates steady at its June meeting, but policymakers indicated that two more rate hikes could come by the end of the year.

In the fixed income market, returns were generally positive across most sectors as investors benefited from the higher interest rates that have become available over the past year. Investment-grade corporate bonds were supported by generally solid balance sheets and were among the strongest performers.

Global economies and markets showed surprising resilience in recent months, but, moving into the second half of 2023, we believe investors could face potential challenges. The impact of the Fed's rate hikes has yet to be fully felt in the economy, and while the regional banking turmoil appears to have been contained by the swift actions of regulators, it could weigh on credit conditions. Moreover, market consensus still seems to point to a coming recession, although hopes have emerged that such a downturn could be more modest. We believe this environment makes skilled active management a critical tool for identifying risks and opportunities, and our investment teams will continue to use fundamental research to identify securities that can add value to your portfolio over the long term.

You may notice that this report no longer contains the commentary on your fund's performance and positioning that we previously included in the semiannual shareholder letters. The Securities and Exchange Commission (SEC) adopted new rules in January that will require fund reports to transition to a new format known as a Tailored Shareholder Report. This change will require a much more concise summary of performance rather than the level of detail we have provided historically while also aiming to be more visually engaging. As we prepare to make changes to the annual reports to meet the new report regulatory requirements by mid-2024, we felt the time was right to discontinue the optional six-month semiannual fund letter to focus on the changes to come.

While semiannual fund letters will no longer be produced, you may continue to access current fund information as well as insights and perspectives from our investment team on our personal investing website.

Thank you for your continued confidence in T. Rowe Price.

Sincerely,

polit fr. Shanfre

Robert Sharps CEO and President

Portfolio Summary

-

SECTOR DIVERSIFICATION

	Percent of I	Vet Assets
	12/31/22	6/30/23
Information Technology	47.0%	43.1%
Communication Services	12.8	15.1
Consumer Discretionary	14.5	14.5
Health Care	16.7	12.7
Financials	5.1	10.2
Industrials and Business Services	2.0	2.1
Materials	1.3	1.0
Consumer Staples	0.0	0.6
Utilities	0.0	0.2
Energy	0.0	0.0
Real Estate	0.0	0.0
Other and Reserves	0.6	0.5
Total	100.0%	100.0%

Historical weightings reflect current industry/sector classifications.

TWENTY-FIVE LARGEST HOLDINGS

	Percent of Net Assets 6/30/23
Microsoft	14.0%
Apple	11.3
Amazon.com	7.7
Alphabet	7.5
NVIDIA	5.9
Meta Platforms	5.0
UnitedHealth Group	3.3
Visa	3.3
Tesla	2.9
Mastercard	2.7
Eli Lilly	2.7
ServiceNow	2.2
Intuitive Surgical	1.7
Netflix	1.5
ASML Holding	1.4
Thermo Fisher Scientific	1.3
Intuit	1.2
Synopsys	1.2
Chipotle Mexican Grill	1.0
T-Mobile U.S.	1.0
Chubb	1.0
Advanced Micro Devices	0.9
Booking Holdings	0.8
Roper Technologies	0.7
Danaher	0.7
Total	82.9%

Note: The information shown does not reflect any exchange-traded funds (ETFs), cash reserves, or collateral for securities lending that may be held in the portfolio.

FUND EXPENSE EXAMPLE

As a mutual fund shareholder, you may incur two types of costs: (1) transaction costs, such as redemption fees or sales loads, and (2) ongoing costs, including management fees, distribution and service (12b-1) fees, and other fund expenses. The following example is intended to help you understand your ongoing costs (in dollars) of investing in the fund and to compare these costs with the ongoing costs of investing in other mutual funds. The example is based on an investment of \$1,000 invested at the beginning of the most recent six-month period and held for the entire period.

Shares of the fund are currently offered only through certain insurance companies as an investment medium for both variable annuity contracts and variable life insurance policies. Please note that the fund has two classes of shares: the original share class and the II Class. The II Class shares are sold through financial intermediaries, which are compensated for distribution, shareholder servicing, and/or certain administrative services under a Board-approved Rule 12b-1 plan.

Actual Expenses

The first line of the following table (Actual) provides information about actual account values and actual expenses. You may use the information on this line, together with your account balance, to estimate the expenses that you paid over the period. Simply divide your account value by \$1,000 (for example, an \$8,600 account value divided by \$1,000 = 8.6), then multiply the result by the number on the first line under the heading "Expenses Paid During Period" to estimate the expenses you paid on your account during this period.

Hypothetical Example for Comparison Purposes

The information on the second line of the table (Hypothetical) is based on hypothetical account values and expenses derived from the fund's actual expense ratio and an assumed 5% per year rate of return before expenses (not the fund's actual return). You may compare the ongoing costs of investing in the fund with other funds by contrasting this 5% hypothetical example and the 5% hypothetical examples that appear in the shareholder reports of the other funds. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period.

You should also be aware that the expenses shown in the table highlight only your ongoing costs and do not reflect any transaction costs, such as redemption fees or sales loads. Therefore, the second line of the table is useful in comparing ongoing costs only and will not help you determine the relative total costs of owning different funds. To the extent a fund charges transaction costs, however, the total cost of owning that fund is higher.

BLUE CHIP GROWTH PORTFOLIO

	Beginning Account Value 1/1/23	Ending Account Value 6/30/23	Expenses Paid During Period* 1/1/23 to 6/30/23
Blue Chip Growth Portfolio			
Actual	\$1,000.00	\$1,349.70	\$4.37
Hypothetical (assumes 5% return before expenses)	1,000.00	1,021.08	3.76
Blue Chip Growth Portfolio -	II		
Actual	1,000.00	1,348.60	5.82
Hypothetical (assumes 5% return before expenses)	1,000.00	1,019.84	5.01

Expenses are equal to the fund's annualized expense ratio for the 6-month period, multiplied by the average account value over the period, multiplied by the number of days in the most recent fiscal half year (181), and divided by the days in the year (365) to reflect the half-year period. The annualized expense ratio of the Blue Chip Growth Portfolio was 0.75%, and the Blue Chip Growth Portfolio - II was 1.00%. (Unaudited)

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period

Blue Chip Growth Portfolio Class	6 Months Ended 6/30/23	Year Ended 12/31/22	12/31/21	12/31/20	12/31/19	12/31/18
NET ASSET VALUE	0,00,20	, ,	, ,	, ,	, ,	, ,
Beginning of period	\$ 30.94	\$ 53.12	\$ 50.71	\$ 38.98	\$ 30.79	\$ 31.22
Investment activities						
Net investment income (loss) ⁽¹⁾⁽²⁾ Net realized and unrealized gain/	(0.01)	(0.09)	(0.24)	(0.14)	_(3)	_(3)
loss	10.83	(20.36)	9.00	13.50	9.19	0.61
Total from investment activities	10.82	(20.45)	8.76	13.36	9.19	0.61
Distributions						
Net realized gain		(1.73)	(6.35)	(1.63)	(1.00)	(1.04)
NET ASSET VALUE End of period	\$ 41.76	\$ 30.94	\$ 53.12	\$ 50.71	\$ 38.98	\$ 30.79
Ratios/Supplemental Data						
Total return ⁽²⁾⁽⁴⁾	34.97%	(38.50)%	17.62%	34.28%	29.89%	1.92%
Ratios to average net assets: ⁽²⁾ Gross expenses before waivers/						
payments by Price Associates ⁽⁵⁾ Net expenses after waivers/	0.85%(6)	0.85%	0.85%	0.85%	0.85%	0.80%
payments by Price Associates	0.75%(6)	0.75%	0.75%	0.75%	0.75%	0.80%
Net investment income (loss)	(0.08)% ⁽⁶⁾	(0.24)%	(0.42)%	(0.33)%	0.01%	(0.01)%
Portfolio turnover rate Net assets, end of period (in	7.8%	18.0%	38.2%	27.1%	31.6%	30.1%
thousands)	\$ 1,268,149	\$ 1,055,580	\$ 1,771,014	\$ 1,606,413	\$ 1,199,110	\$ 950,220

⁽¹⁾ Per share amounts calculated using average shares outstanding method.

⁽²⁾ See Note 6 for details of expense-related arrangements with Price Associates.

⁽³⁾ Amounts round to less than \$0.01 per share.

⁽⁴⁾ Total return reflects the rate that an investor would have earned on an investment in the fund during each period, assuming reinvestment of all distributions, and payment of no redemption or account fees, if applicable. Total return is not annualized for periods less than one year.

⁽⁵⁾ See Note 6. Prior to 12/31/19, the gross expense ratios presented are net of a management fee waiver in effect during the period, as applicable.
 ⁽⁶⁾ Annualized

(Unaudited)

FINANCIAL HIGHLIGHTS

For a share outstanding throughout each period

Blue Chip Growth Portfolio - II Class

Class												
		6 Months		Year Ended								
		Ended				10/01/01		10/01/00		10/01/10		10/01/10
		6/30/23		12/31/22		12/31/21		12/31/20		12/31/19		12/31/18
NET ASSET VALUE	•		•	50.47	•	10.10	.	07.40	.	~~~~	•	
Beginning of period	. \$	29.23	\$	50.47	_ \$	48.48	\$	37.42	\$	29.66	\$	30.19
Investment activities												
Net investment loss ⁽¹⁾⁽²⁾		(0.06)		(0.18)		(0.36)		(0.24)		(0.08)		(0.09)
Net realized and unrealized gain/		(0.00)		(0.10)		(0.50)		(0.24)		(0.00)		(0.03)
loss		10.25		(19.33)		8.59		12.93		8.84		0.60
Total from investment activities		10.19		(19.51)		8.23		12.69		8.76		0.51
Distributions												
Net realized gain		-		(1.73)		(6.24)		(1.63)		(1.00)		(1.04)
NET ASSET VALUE	¢	39.42	¢	29.23	\$	50.47	\$	48.48	\$	37.42	\$	29.66
End of period	\$	39.42	\$	29.23	Þ	50.47	φ	40.40	Ф	37.42	Þ	29.00
Ratios/Supplemental Data												
Total return ⁽²⁾⁽³⁾		34.86%		(38.66)%		17.33%		33.92%		29.58%		1.65%
Ratios to average net assets: ⁽²⁾												
Gross expenses before waivers/		1 100((5)		1 1 0 0 /		1 100/		1 100/		1 100/		1.050/
payments by Price Associates ⁽⁴⁾		1.10%(5)		1.10%		1.10%		1.10%		1.10%		1.05%
Net expenses after waivers/		1.00%(5)		1.00%		1.00%		1.00%		1.00%		1.05%
payments by Price Associates		1.00%(%)				(0.67)%		(0.57)%		(0.24)%		(0.27)%
Not invortment loss		(0 22)0/ (5)						10.371%		(U.24)%		(0.27)%
Net investment loss		(0.33)% ⁽⁵⁾		(0.49)%		(0.07)/0						
Net investment loss Portfolio turnover rate		(0.33)% ⁽⁵⁾ 7.8%		18.0%		38.2%		27.1%		31.6%		30.1%

⁽¹⁾ Per share amounts calculated using average shares outstanding method.

⁽²⁾ See Note 6 for details of expense-related arrangements with Price Associates.

(3) Total return reflects the rate that an investor would have earned on an investment in the fund during each period, assuming reinvestment of all distributions, and payment of no redemption or account fees, if applicable. Total return is not annualized for periods less than one year.

⁽⁴⁾ See Note 6. Prior to 12/31/19, the gross expense ratios presented are net of a management fee waiver in effect during the period, as applicable.

(5) Annualized

June 30, 2023 (Unaudited)

PORTFOLIO OF INVESTMENTS [‡]	Shares/Par	\$ Value
(Cost and value in \$000s)		
COMMON STOCKS 99.2%		
COMMUNICATION SERVICES 15.2%		
Entertainment 1.7%		
Netflix (1)	61,143	26,933
Sea, ADR (1)	87,449	5,075
		32,008
Interactive Media & Services 12.5%		
Alphabet, Class A (1)	201,370	24,104
Alphabet, Class C (1) Meta Platforms, Class A (1)	946,180 319,258	114,459 91 621
		230,184
Wireless Telecommunication Services 1.0%		230,104
T-Mobile U.S. (1)	127,611	17,725
		17,725
Total Communication Services CONSUMER		279,917
DISCRETIONARY 14.4%		
Automobiles 2.9%		
Tesla (1)	208,189	54,498
		54,498
Broadline Retail 7.7%		
Amazon.com (1)	1,091,346	142,268
Hotels, Restaurants & Leisure 2.0%		142,268
Booking Holdings (1)	5,366	
Chipotle Mexican Grill (1)	50 839	19,088
DoorDash, Class A (1)		3,885
Specialty Retail 1.0%		37,463
Ross Stores TJX	95,771 97,212	10,739 8,242
	57,212	18,981
Textiles, Apparel & Luxury Goods 0.8%		
Lululemon Athletica (1)	22,932	8,680
NIKE, Class B	60,659	6,695
		15,375
Total Consumer Discretionary CONSUMER STAPLES 0.6%		268,585
Consumer Staples Distribution & Retail 0.6%		
Dollar General	66,917	11,361
Total Consumer Staples FINANCIALS 10.1%		11,361
Capital Markets 1.7%		
Charles Schwab	101,469	5,751
Goldman Sachs Group	15 602	5,033
Morgan Stanley	104,096	8,890
MSCI	5,164	2,423

(Cost and value in \$000s) S&P Global 25,248 10,122 Financial Services 6.8% 32,219 Adyen (EUR) (1) 3,703 6,412 Affirm Holdings (1) 44,983 690 ANT International, Class C, Acquisition 128,402 1294 Block, Class A (1) 43,993 2,929 Fiser (1) 31,925 4,027 Mastercard, Class A (1) 43,993 2,929 Visa, Class A (1) 43,993 2,929 Visa, Class A (1) 41,25,685 49,432 Visa, Class A (1) 25,647 60,432 Insurance 1.6% 125,216 Insurance 1.6% Chubb 91,442 17,608 Marsh & McLennan 66,259 12,462 30,070 Total Financials 187,505 HEALTH CARE 12,7% Health Care Equipment & Supplies 2,6% Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 14,841 Health Care Providers & Services 1,3% Elevance Health 1,5161 6,736		Shares/Par	\$ Value
32.219 Financial Services 6.8% Adyen (EUR) (1) 3,703 6,412 Affirm Holdings (1) 44,983 690 ANT International, Class C, Acquisition 1,294 1,294 Block, Class A (1) 43,993 2,929 Fiserv (1) 31,925 4,027 Mastercard, Class A 125,685 49,432 Visa, Class A 254,472 60,432 Insurance 1.6% 125,216 125,216 Chubb 91,442 17,608 Marsh & McLennan 66,259 12,462 30,070 70tal Financials 187,505 HEALTH CARE 12.7% Health Care Equipment & Supplies 2.6% 38,085 Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 Health Care Providers & Services 4.3% 80,339 Elevance Health 15,161 6,736 Humana 28,547 12,764	(Cost and value in \$000s)		
Financial Services 6.8% Adyen (EUR) (1) 3,703 6,412 Affirm Holdings (1) 44,983 690 ANT International, Class C, Acquisition Date: 6/7/18, Cost \$2,803 (2)(3) 735,429 1,294 Block, Class A (1) 43,993 2,929 1,294 Block, Class A (1) 31,925 4,027 Mastercard, Class A 125,685 49,432 Visa, Class A 256,85 49,432 Visa, Class A 256,472 60,432 Insurance 1.6% 125,216 125,216 Chubb 91,442 17,608 Marsh & McLennan 66,259 12,462 30,070 Total Financials 187,505 HEALTH CARE 12.7% Health Care Equipment & Supplies 2.6% 30,070 Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 Health Care Providers & Services 4.3% 84,411 Elevance Health 15,161 6,736 Humana 28,547 12,764 <td>S&P Global</td> <td>25,248</td> <td>10,122</td>	S&P Global	25,248	10,122
Adyen (EUR) (1) 3,703 6,412 Affirm Holdings (1) 44,983 690 ANT International, Class C, Acquisition Date: 6/7/18, Cost \$2,803 (2)(3) 735,429 1.294 Block, Class A (1) 43,993 2.929 Fiserv (1) 31,925 4.027 Mastercard, Class A (1) 43,993 2.929 Fiserv (1) 31,925 4.027 Mastercard, Class A (1) 43,993 2.929 Fiserv (1) 31,925 4.027 Mastercard, Class A (125,685 49,432 Visa, Class A 254,472 60,432 Insurance 1.6% Chubb 91,442 17,608 Marsh & McLennan 66,259 12,462 30,070 Total Financials 187,505 HEALTH CARE 12.7% Health Care Equipment & Supplies 2.6% Align Technology (1) 7,259 2.567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 48,441 Health Care Providers & Services 4.3% Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 80,339 Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 Pharmaceuticals 3.5% AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 Total Health Care 125,578 SERVICES 2.2% Aerospace & Defense 0.3% TransDigm Group 5,300 4,739 Commercial Services & Supplies 0.2% Cintas 6,092 3,028	Einensial Services 6 9%		32,219
Affirm Holdings (1) 44,983 690 ANT International, Class C, Acquisition 1294 Block, Class A (1) 43,993 2,929 Fisery (1) 31,925 4,027 Mastercard, Class A 125,685 49,432 Visa, Class A 125,685 49,432 Visa, Class A 125,685 49,432 Insurance 1.6% 125,216 125,216 Chubb 91,442 17,608 Marsh & McLennan 66,259 12,462 30,070 30,070 30,070 Total Financials 187,505 187,505 HEALTH CARE 12.7% Health Care Equipment & Supplies 2.6% 30,085 Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,611 Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 Boaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 Danaher 54,		2 702	6 410
ANT International, Class C, Acquisition Date: 6/7/18, Cost \$2,803 (2)(3) 735,429 1,294 Block, Class A (1) 43,993 2,929 Fiser (1) 31,925 4,027 Mastercard, Class A 125,685 49,432 Visa, Class A 254,472 60,432 Insurance 1.6% Chubb 91,442 17,608 Marsh & MoLennan 66,259 12,462 30,070 Total Financials 187,505 HEALTH CARE 12.7% Health Care Equipment & Supplies 2.6% Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 Health Care Providers & Services 4.3% Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 StryZeneca, ADR 71,129 5,091 El Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% TransDigm Group 5,300 4,739 Commercial Services & Supplies 0.2% Cintas 6,092 3,028			
Date: 6/7/18, Cost \$2,803 (2)(3) 735,429 1,294 Block, Class A (1) 43,993 2,929 Fiserv (1) 31,925 4,027 Mastercard, Class A 125,685 49,432 Visa, Class A 254,472 60,432 Insurance 1.6% 125,216 125,216 Insurance 1.6% 91,442 17,608 Chubb 91,442 17,608 Marsh & McLennan 66,259 12,462 30,070 Total Financials 187,505 HEALTH CARE 12.7% Health Care Equipment & 30,070 Total Financials 187,505 41,619 Supplies 2.6% Align Technology (1) 7,259 2,567 Align Technology (1) 7,259 2,567 11,108 2,689 Intuitive Surgical (1) 92,315 31,566 517,98 60,839 Beervices 4.3% Elevance Health 15,161 6,736 Health Care Providers & 80,339 80,339 Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4			030
Block, Class A (1) 43,993 2,929 Fisery (1) 31,925 4,027 Mastercard, Class A 125,685 49,432 Visa, Class A 256,855 49,432 Visa, Class A 256,855 49,432 Visa, Class A 256,472 60,432 Insurance 1.6% 125,216 125,216 Insurance 1.6% 91,442 17,608 Marsh & McLennan 66,259 12,462 30,070 187,505 Health Care Equipment & Supplies 2.6% 187,505 Health Care Equipment & Supplies 2.6% 187,505 11,619 Teleflex 11,108 2,685 11,619 Teleflex 11,108 2,685 11,619 Teleflex 11,108 2,686 48,441 Health Care Providers & Services 4.3% 28,547 12,764 Elevance Health 15,161 6,736 60,839 Humana 28,547 12,764 46,19 Life Sciences Tools & Services 2.0% 30,339 4,619 4,619 Life		735,429	1,294
Mastercard, Class A 125,685 49,432 Visa, Class A 254,472 60,432 Insurance 1.6% 125,216 Chubb 91,442 17,608 Marsh & McLennan 66,259 12,422 30,070 Total Financials 187,505 HEALTH CARE 12.7% Health Care Equipment & 30,070 Health Care Equipment & Supplies 2.6% 11,619 Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 48,441 Services 4.3% 48,441 Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 Barbin Care Technology 0.3% 80,339 46,619 Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 20,91 37,438 Danaher 54,171 13,001 <		43,993	2,929
Mastercard, Class A 125,685 49,432 Visa, Class A 254,472 60,432 Insurance 1.6% 125,216 Chubb 91,442 17,608 Marsh & McLennan 66,259 12,462 30,070 Total Financials 187,505 HEALTH CARE 12.7% 187,505 187,505 Health Care Equipment & Supplies 2.6% 11,018 2,689 Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleftex 11,108 2,689 Health Care Providers & Services 4.3% 84,441 Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 Banaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 StarZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,1	Fiserv (1)	31,925	4,027
Insurance 1.6% 125,216 Chubb 91,442 17,608 Marsh & McLennan 66,259 12,462 30,070 30,070 Total Financials 187,505 HEALTH CARE 12.7% Health Care Equipment & Supplies 2.6% Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 48,441 48,441 Health Care Providers & Services 4.3% Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 Health Care Technology 0.3% 80,339 80,339 4619 4,619 Life Sciences Tools & Services 2.0% 23,362 4,619 4,619 Life Sciences Tools & Services 2.0% 20,913 10,242 64,506 Danaher 54,171 13,001 11,048,81 49,173 20,913 10,242 Eli Lilly 104,851 49,173 2	Maataraard Class A		49,432
Insurance 1.6% 91,442 17,608 Marsh & McLennan 66,259 12,462 30,070 30,070 Total Financials 187,505 HEALTH CARE 12.7% Health Care Equipment & Supplies 2.6% Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 48,441 48,441 Health Care Providers & Services 4.3% Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 Health Care Technology 0.3% 80,339 80,339 80,339 80,339 Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 24,437 37,438 Pharmaceuticals 3.5% 4 49,173 20,091 AstraZeneca, ADR 71,129 5,091 11,104 Ih Lifly 104,851 49,173 20,242 <td>Visa, Class A</td> <td>254,472</td> <td>60,432</td>	Visa, Class A	254,472	60,432
Chubb 91,442 17,608 Marsh & McLennan 66,259 12,462 30,070 30,070 Total Financials 187,505 HEALTH CARE 12.7% Health Care Equipment & Supplies 2.6% Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 Health Care Providers & 48,441 Health Care Providers & 48,441 Health Care Providers & 5ervices 4.3% Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 80,339 80,339 80,339 Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 24,437 37,438 Pharmaceuticals 3.5% 31,129 5,091 Strip Sizer Scientific 46,836 24,437 104,851 49,173	Insurance 1.6%		125,216
Marsh & McLennan 66,259 12,462 30,070 30,070 Total Financials 187,505 HEALTH CARE 12.7% 187,505 Health Care Equipment & Supplies 2.6% 187,505 Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 48,441 48,441 Health Care Providers & Services 4.3% 48,441 Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 80,339 80,339 80,339 Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 24,619 4,619 Danaher 54,171 13,001 1 Thermo Fisher Scientific 46,836 24,437 37,438 9,473 10,242 Gotis 59,473 10,242		91 //2	17 608
30,070 Total Financials 187,505 HEALTH CARE 12.7% Health Care Equipment & Supplies 2.6% Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 Health Care Providers & Services 4.3% 48,441 Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 Health Care Technology 0.3% 80,339 80,339 Health Care Technology 0.3% 23,362 4,619 Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 4,619 4,619 Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 StraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 Mathealth Care 235,343			
Total Financials 187,505 HEALTH CARE 12.7% Health Care Equipment & Supplies 2.6% Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 48,441 48,441 Health Care Providers & Services 4.3% 80,835 12,764 Elevance Health 15,161 6,736 60,839 Humana 28,547 12,764 0,0339 Health Care Technology 0.3% 80,339 80,339 Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 4,619 4,619 4,619 Life Sciences Tools & Services 2.0% 59,471 13,001 71,129 5,091 Danaher 54,171 13,001 71,129 5,091 64,506 Total Health Care 235,343 10,242 64,506 64,506 Total Health Care 235,343 10,242 64,506 64,506 <t< td=""><td></td><td></td><td></td></t<>			
HEALTH CARE 12.7% Health Care Equipment & Supplies 2.6% Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 Health Care Providers & Services 4.3% Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 Health Care Technology 0.3% 80,339 Health Care Technology 0.3% 4,619 Life Sciences Tools & Services 2.0% 4,619 Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 7,438 Pharmaceuticals 3.5% 59,473 10,242 Cotts 59,473 10,242 64,506 23,343 10,042 INDUSTRIALS & BUSINESS 58 58 SERVICES 2.2% 4 4,739 Aerospace & Defense 0.3% 7,739 0,242 4,739 5,300 4,739			
Health Care Equipment & Supplies 2.6% Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 Health Care Providers & Services 4.3% Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 Health Care Technology 0.3% 80,339 Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 4,619 4,619 Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 AstraZeneca, ADR 71,129 5,091 Eli Liliy 104,851 49,173 Zoetis 59,473 10,242 64,506 59,473 10,242 Cotal Health Care 235,343 10,0425 INDUSTRIALS & BUSINESS SERVICES 2.2% 4,739 Aerospace & Defense 0.3% 4,739 4,739			187,505
Supplies 2.6% Align Technology (1) 7,259 2,567 Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 48,441 Health Care Providers & 38,085 11,619 Services 4.3% 15,161 6,736 Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 80,339 80,339 80,339 Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 9 4,619 4,619 Danaher 54,171 13,001 7,438 74,438 Pharmaceuticals 3.5% AstraZeneca, ADR 71,129 5,091 59,473 10,242 Cotal Health Care 235,343 10,242 64,506 64,506 Total Health Care 235,343 10,242 64,506 10,435 47.39 10,242			
Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 48,441 Health Care Providers & Services 4.3% Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 80,339 Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4,619 4,619 Life Sciences Tools & Services 2.0% Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 Pharmaceuticals 3.5% AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% TransDigm Group 5,300 4,739 4,739 Commercial Services & Supplies 0.2% Cintas 6,092 3,028			
Intuitive Surgical (1) 92,315 31,566 Stryker 38,085 11,619 Teleflex 11,108 2,689 48,441 Health Care Providers & Services 4.3% Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 80,339 Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4,619 4,619 Life Sciences Tools & Services 2.0% Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 Pharmaceuticals 3.5% AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% TransDigm Group 5,300 4,739 4,739 Commercial Services & Supplies 0.2% Cintas 6,092 3,028	Align Technology (1)	7,259	2,567
Stryker 38,085 11,619 Teleflex 11,108 2,689 48,441 48,441 Health Care Providers & 38,085 48,441 Health Care Providers & 38,085 11,619 Services 4.3% 15,161 6,736 Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 80,339 80,339 80,339 Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 46,19 46,19 46,19 Danaher 54,171 13,001 7,438 Pharmaceuticals 3.5% 37,438 74,836 24,437 AstraZeneca, ADR 71,129 5,091 59,473 10,242 64,506 59,473 10,242 64,506 Total Health Care 235,343 10,242 64,506 Total Health Care 235,343 10,242 64,506 SERVICES 2.2% Aerospace & Defense 0.3% 4,739 4,739 Com	Intuitive Surgical (1)	92,315	31,566
48,441 Health Care Providers & Services 4.3% Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 Health Care Technology 0.3% 80,339 Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 4,619 Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 64,506 Total Health Care 235,343 10,242 64 59,473 10,242 64 506 7,39 TransDigm Group 5,300 4,739 Commercial Services & 4,739 Commercial Services & 5,002 3,028			11,619
Health Care Providers & Services 4.3% Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 80,339 80,339 Health Care Technology 0.3% 80,339 Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 4,619 Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% 4,739 Aerospace & Defense 0.3% 4,739 4,739 TransDigm Group 5,300 4,739 Commercial Services & 3,028 4,739	Teleflex	11,108	2,689
Services 4.3% Elevance Health 15,161 6,736 Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 80,339 80,339 Health Care Technology 0.3% 80,339 Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 4,619 Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% 4,739 TransDigm Group 5,300 4,739 4,739 4,739 4,739 Commercial Services & Supplies 0.2% 6,092 3,028			48,441
Humana 28,547 12,764 UnitedHealth Group 126,578 60,839 80,339 80,339 Health Care Technology 0.3% 80,339 Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 4,619 Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 37,438 Pharmaceuticals 3.5% 37,438 AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 64,506 Total Health Care 235,343 10,242 INDUSTRIALS & BUSINESS SERVICES 2.2% 4,739 Aerospace & Defense 0.3% 4,739 4,739 TransDigm Group 5,300 4,739 Commercial Services & Supplies 0.2% 6,092 3,028			
UnitedHealth Group 126,578 60,839 Nealth Care Technology 0.3% 80,339 Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 4,619 Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 64,506 Total Health Care 235,343 10,242 INDUSTRIALS & BUSINESS SERVICES 2.2% 4,739 Aerospace & Defense 0.3% 4,739 4,739 Commercial Services & Supplies 0.2% 6,092 3,028	Elevance Health	15,161	6,736
80,339 Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 4,619 Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 37,438 Pharmaceuticals 3.5% 37,438 AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% 4,739 TransDigm Group 5,300 4,739	Humana	28,547	12,764
Health Care Technology 0.3% Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 4619 Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 37,438 Pharmaceuticals 3.5% 37,438 AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 64,506 Total Health Care 235,343 100USTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% 4,739 Commercial Services & Supplies 0.2% 6,092 3,028	UnitedHealth Group	126,578	60,839
Veeva Systems, Class A (1) 23,362 4,619 Life Sciences Tools & Services 2.0% 4,619 Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 64,506 Total Health Care 235,343 10,242 INDUSTRIALS & BUSINESS SERVICES 2.2% 4,739 Aerospace & Defense 0.3% 4,739 4,739 Commercial Services & Supplies 0.2% 6,092 3,028			80,339
4,619 Life Sciences Tools & Services 2.0% Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 Pharmaceuticals 3.5% AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% 4,739 Commercial Services & 4,739 Commercial Services & 5,300 4,739 Contas 6,092 3,028			
Life Sciences Tools & Services 2.0% Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 Pharmaceuticals 3.5% AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% TransDigm Group 5,300 4,739 4,739 Commercial Services & Supplies 0.2% Cintas 6,092 3,028	Veeva Systems, Class A (1)	23,362	4,619
Danaher 54,171 13,001 Thermo Fisher Scientific 46,836 24,437 37,438 37,438 Pharmaceuticals 3.5% AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% 4,739 TransDigm Group 5,300 4,739 Commercial Services & Supplies 0.2% 6,092 3,028			4,619
Thermo Fisher Scientific 46,836 24,437 37,438 37,438 Pharmaceuticals 3.5% 37,438 AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% 4,739 TransDigm Group 5,300 4,739 Commercial Services & Supplies 0.2% 6,092 3,028	Life Sciences Tools & Services 2.0%		
37,438 Pharmaceuticals 3.5% AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% 4,739 TransDigm Group 5,300 4,739 Commercial Services & Supplies 0.2% 6,092 3,028	Danaher		
Pharmaceuticals 3.5% AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% 4,739 TransDigm Group 5,300 4,739 Commercial Services & Supplies 0.2% 6,092 3,028	Thermo Fisher Scientific		
Pharmaceuticals 3.5% AstraZeneca, ADR 71,129 5,091 Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% 4,739 TransDigm Group 5,300 4,739 Commercial Services & Supplies 0.2% 6,092 3,028			37,438
Eli Lilly 104,851 49,173 Zoetis 59,473 10,242 64,506 64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% 7 TransDigm Group 5,300 4,739 Commercial Services & Supplies 0.2% 6,092 3,028	Pharmaceuticals 3.5%		
64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% 7 TransDigm Group 5,300 4,739 Commercial Services & Supplies 0.2% 4,092 3,028			
64,506 Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% 7 TransDigm Group 5,300 4,739 Commercial Services & Supplies 0.2% 4,092 3,028		104,851	49,173
Total Health Care 235,343 INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% TransDigm Group 5,300 4,739 4,739 Commercial Services & Supplies 0.2% Cintas 6,092 3,028	Zoetis		
INDUSTRIALS & BUSINESS SERVICES 2.2% Aerospace & Defense 0.3% TransDigm Group 5,300 4,739 4,739 Commercial Services & Supplies 0.2% Cintas 6,092 3,028			
SERVICES 2.2% Aerospace & Defense 0.3% TransDigm Group 5,300 4,739 Commercial Services & Supplies 0.2% Cintas 6,092 3,028			235,343
TransDigm Group 5,300 4,739 4,739 4,739 Commercial Services & 4,739 Supplies 0.2% 3,028			
4,739 Commercial Services & Supplies 0.2% Cintas 6,092 3,028	Aerospace & Defense 0.3%		
4,739 Commercial Services & Supplies 0.2% Cintas 6,092 3,028	TransDigm Group	5,300	4,739
Commercial Services & Supplies 0.2% Cintas 6,092 3,028			
Cintas 6,092 3,028			
		6 000	2 000
3,028	Uiiilaə		
			3,028

	Shares/Par	\$ Value
(Cost and value in \$000s)		
Ground Transportation 0.4%		
Old Dominion Freight Line	18,452	6,823
		6,823
Industrial Conglomerates 1.2%		
General Electric	82,793	9,095
Roper Technologies	27,670	13,304
Professional Services 0.1%		22,399
Paycom Software	4,818	1,548
		1,548
Total Industrials & Business Services		38,537
INFORMATION TECHNOLOGY 42.8%		
Electronic Equipment, Instruments		
& Components 0.2%		
TE Connectivity	24,412	3,422
		3,422
IT Services 1.5%		
MongoDB (1)	28,357	11,654
Shopify, Class A (1)	176,604	11,409
Snowflake, Class A (1)	23,373	4,113
Semiconductors & Semiconductor		27,176
Equipment 9.9%	111.000	10,100
Advanced Micro Devices (1) ASML Holding	144,690 34,923	16,482 25,311
Lam Research	4,759	3,059
Marvell Technology	91,926	5,495
Monolithic Power Systems	20,125	10,872
NVIDIA	258,561	109,377
Taiwan Semiconductor Manufacturing,		
ADR	64,586	6,518
Texas Instruments	36,015	6,483
Software 19.9%		183,597
Atlassian, Class A (1)	37,400	6,276
BILL Holdings (1)	52,017	6,078
Canva, Acquisition Date: 8/16/21 -		
12/17/21, Cost \$2,456 (1)(2)(3)	1,441	1,022
Confluent, Class A (1)	72,940	2,576
Crowdstrike Holdings, Class A (1)	15,919	2,338
Datadog, Class A (1) Fortinet (1)	32,257 36,555	3,173 2,763
Gusto, Acquisition Date: 10/4/21,		2,703
Cost \$805 (1)(2)(3)	27,971	527
Intuit	49,334	22,604
Microsoft	759,657	258,694
ServiceNow (1)	73,555	41,336
Synopsys (1)	49,048	21,356
		368,743

	Shares/Par	\$ Value
Cost and value in \$000s)		
Technology Hardware, Storage & Peripherals 11.3%		
Apple	1,077,150	208,935
		208,935
Total Information Technology MATERIALS 1.0%		791,873
Chemicals 1.0%		
Linde Sherwin-Williams	23,464 32,606	8,942 8,657
Total Materials UTILITIES 0.2%		17,599
Electric Utilities 0.2%		
Constellation Energy	47,411	4,340
Total Utilities		4,340
Total Common Stocks (Cost		
\$785,110)		1,835,060
CONVERTIBLE PREFERRED STOC	KS 0.2%	
INFORMATION TECHNOLOGY 0.2%		
Software 0.2%		
Canva, Series A, Acquisition Date: 11/4/21 - 12/17/21, Cost \$157 (1)(2) (3)	92	65
Canva, Series A-3, Acquisition Date: 11/4/21 - 12/17/21, Cost \$17 (1)(2)(3)		7
	12,546	918
Databricks, Series H, Acquisition Date: 8/31/21, Cost \$2,305 (1)(2)(3) Gusto, Series E, Acquisition Date:	31,368	2,295
7/13/21, Cost \$1,126 (1)(2)(3)	37,063	698
Total Information Technology		3,983
Total Convertible Preferred Stocks (Cost \$4,347)		3,983
CORPORATE BONDS 0.2%		
Carvana, 10.25%, 5/1/30 (4)	4,175,000	3,215
Total Corporate Bonds (Cost \$4,175)		3,215
SHORT-TERM INVESTMENTS 0.4%	, D	
Money Market Funds 0.4%		
T. Rowe Price Government Reserve Fund, 5.13% (5)(6)	7,234,308	7,234
Total Short-Term Investments (Cost \$7,234)		7,234
Total Investments in Securities 100.0% of Net Assets		
(Cost \$800,866)	\$	1,849,492

- ‡ Shares/Par are denominated in U.S. dollars unless otherwise noted.
- (1) Non-income producing
- (2) See Note 2. Level 3 in fair value hierarchy.
- (3) Security cannot be offered for public resale without first being registered under the Securities Act of 1933 and related rules ("restricted security"). Acquisition date represents the day on which an enforceable right to acquire such security is obtained and is presented along with related cost in the security description. The fund may have registration rights for certain restricted securities. Any costs related to such registration are generally borne by the issuer. The aggregate value of restricted securities (excluding 144A holdings) at period end amounts to \$6,826 and represents 0.4% of net assets.
- (4) Security was purchased pursuant to Rule 144A under the Securities Act of 1933 and may be resold in transactions exempt from registration only to qualified institutional buyers. Total value of such securities at period-end amounts to \$3,215 and represents 0.2% of net assets.
- (5) Seven-day yield
- (6) Affiliated Companies
- ADR American Depositary Receipts
- EUR Euro

AFFILIATED COMPANIES

(\$000s)

The fund may invest in certain securities that are considered affiliated companies. As defined by the 1940 Act, an affiliated company is one in which the fund owns 5% or more of the outstanding voting securities, or a company that is under common ownership or control. The following securities were considered affiliated companies for all or some portion of the six months ended June 30, 2023. Net realized gain (loss), investment income, change in net unrealized gain/loss, and purchase and sales cost reflect all activity for the period then ended.

	С	hange in Net	
Affiliate	Net Realized Gain (Loss)	Unrealized Gain/Loss	Investment Income
T. Rowe Price Government Reserve Fund, 5.13%	\$ - \$	— \$	118++
Totals	\$ <u> </u> # \$	- \$	118+
Supplementary Investment Schedule			

Affiliate	Value 12/31/22	Purchase Cost	Sales Cost	Value 06/30/23
T. Rowe Price Government Reserve Fund, 5.13%	\$ 15,568	۵	¤ \$	7,234
Total			\$	7,234^

Capital gain distributions from underlying Price funds represented \$0 of the net realized gain (loss).

++ Excludes earnings on securities lending collateral, which are subject to rebates and fees as described in Note 3.

+ Investment income comprised \$118 of dividend income and \$0 of interest income.

^p Purchase and sale information not shown for cash management funds.

^ The cost basis of investments in affiliated companies was \$7,234.

June 30, 2023 (Unaudited)

STATEMENT OF ASSETS AND LIABILITIES

(\$000s, except shares and per share amounts)

Assets Investments in securities, at value (cost \$800,866) Receivable for investment securities sold Receivable for shares sold Dividends and interest receivable Total assets	\$	1,849,492 2,155 1,000 320 1,852,967
Liabilities Payable for investment securities purchased Payable for shares redeemed Investment management and administrative fees payable Other liabilities Total liabilities		1,602 1,424 1,174 120 4,320
NET ASSETS	\$	1,848,647
Net Assets Consist of: Total distributable earnings (loss) Paid-in capital applicable to 45,091,340 shares of \$0.0001 par value capital stock outstanding; 1,000,000,000 shares of the Corporation authorized	\$	975,061 873,586
NET ASSETS	\$	1,848,647
NET ASSET VALUE PER SHARE		
Blue Chip Growth Portfolio Class (Net assets: \$1,268,149; Shares outstanding: 30,364,041) Blue Chip Growth Portfolio - II Class (Net assets: \$580,498; Shares outstanding: 14,727,299)	<u>\$</u>	<u>41.76</u> 39.42

(Unaudited)

STATEMENT OF OPERATIONS

(\$000s)

	6 Months Ended
	6/30/23
Investment Income (Loss)	
Income	
Dividend (net of foreign taxes of \$32)	\$ 4,941
Other, non cash	371
Interest	213
Securities lending	1
Total income	5,526
Expenses	
Investment management and administrative expense	6,998
Rule 12b-1 fees - Blue Chip Growth Portfolio - II Class	627
Waived / paid by Price Associates	(823)
Net expenses	6,802
Net investment loss	(1,276)
Realized and Unrealized Gain / Loss	
Net realized gain (loss)	
Securities	50,603
Foreign currency transactions	(1)
Net realized gain	50,602
Change in net unrealized gain on securities	450.866
Net realized and unrealized gain / loss	501,468
Not rouizou and unrouizou guirry roos	
INCREASE IN NET ASSETS FROM OPERATIONS	<u>\$500,192</u>

(Unaudited)

STATEMENT OF CHANGES IN NET ASSETS

(\$000s)

(\$6665)		
	6 Months	Year
	Ended	Ended
	6/30/23	12/31/22
Increase (Decrease) in Net Assets		
Operations		
Net investment loss	\$ (1,276)	\$ (5,870)
Net realized gain (loss)	50,602	(114,416)
Change in net unrealized gain / loss	450,866	(851,275)
Increase (decrease) in net assets from operations	500,192	(971,561)
Distributions to shareholders		
Net earnings		
Blue Chip Growth Portfolio Class	-	(55,747)
Blue Chip Growth Portfolio - II Class	.	(25,099)
Decrease in net assets from distributions		(80,846)
Capital share transactions*		
Shares sold		
Blue Chip Growth Portfolio Class	115,328	279,904
Blue Chip Growth Portfolio - II Class	45,536	98,745
Distributions reinvested		
Blue Chip Growth Portfolio Class	-	55,747
Blue Chip Growth Portfolio - II Class	-	25,099
Shares redeemed		
Blue Chip Growth Portfolio Class	(250,021)	(324,012)
Blue Chip Growth Portfolio - II Class	(67,497)	(134,022)
Increase (decrease) in net assets from capital share transactions	(156,654)	1,461
Net Assets		
Increase (decrease) during period	343,538	(1,050,946)
Beginning of period	1,505,109	2,556,055
End of period	\$ 1,848,647	\$ 1,505,109
* 01		
*Share information (000s)		
Shares sold	0.400	7 400
Blue Chip Growth Portfolio Class	3,182	7,189
Blue Chip Growth Portfolio - II Class	1,325	2,625
Distributions reinvested		
Blue Chip Growth Portfolio Class	-	1,799
Blue Chip Growth Portfolio - II Class	-	857
Shares redeemed		
Blue Chip Growth Portfolio Class	(6,939)	(8,207)
Blue Chip Growth Portfolio - II Class	(1,975)	(3,658)
Increase (decrease) in shares outstanding	(4,407)	605

Unaudited

NOTES TO FINANCIAL STATEMENTS

T. Rowe Price Equity Series, Inc. (the corporation) is registered under the Investment Company Act of 1940 (the 1940 Act). The Blue Chip Growth Portfolio (the fund) is a nondiversified, open-end management investment company established by the corporation. The fund seeks to provide long-term capital growth. Income is a secondary objective. Shares of the fund currently are offered only to insurance company separate accounts established for the purpose of funding variable annuity contracts and variable life insurance policies. The fund has two classes of shares: the Blue Chip Growth Portfolio (Blue Chip Growth Portfolio Class) and the Blue Chip Growth Portfolio–II (Blue Chip Growth Portfolio–II Class). Blue Chip Growth Portfolio–II Class shares are sold through financial intermediaries, which it compensates for distribution, shareholder servicing, and/or certain administrative services under a Board-approved Rule 12b-1 plan. Each class has exclusive voting rights on matters related solely to that class; separate voting rights on matters that relate to both classes; and, in all other respects, the same rights and obligations as the other class.

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

Basis of Preparation The fund is an investment company and follows accounting and reporting guidance in the Financial Accounting Standards Board (FASB) *Accounting Standards Codification* Topic 946 (ASC 946). The accompanying financial statements were prepared in accordance with accounting principles generally accepted in the United States of America (GAAP), including, but not limited to, ASC 946. GAAP requires the use of estimates made by management. Management believes that estimates and valuations are appropriate; however, actual results may differ from those estimates, and the valuations reflected in the accompanying financial statements may differ from the value ultimately realized upon sale or maturity.

Investment Transactions, Investment Income, and Distributions Investment transactions are accounted for on the trade date basis. Income and expenses are recorded on the accrual basis. Realized gains and losses are reported on the identified cost basis. Premiums and discounts on debt securities are amortized for financial reporting purposes. Income tax-related interest and penalties, if incurred, are recorded as income tax expense. Dividends received from other investment companies are reflected as dividend income; capital gain distributions are reflected as realized gain/loss. Dividend income and capital gain distributions are recorded on the ex-dividend date. Non-cash dividends, if any, are recorded at the fair market value of the asset received. Proceeds from litigation payments, if any, are included in either net realized gain (loss) or change in net unrealized gain/loss from securities. Distributions to shareholders are recorded on the ex-dividend date. Income distributions, if any, are declared and paid by each class annually. A capital gain distribution, if any, may also be declared and paid by the fund annually.

Currency Translation Assets, including investments, and liabilities denominated in foreign currencies are translated into U.S. dollar values each day at the prevailing exchange rate, using the mean of the bid and asked prices of such currencies against U.S. dollars as provided by an outside pricing service. Purchases and sales of securities, income, and expenses are translated into U.S. dollars at the prevailing exchange rate on the respective date of such transaction. The effect of changes in foreign currency exchange rates on realized and unrealized security gains and losses is not bifurcated from the portion attributable to changes in market prices.

Class Accounting Investment income, investment management and administrative expense, and realized and unrealized gains and losses are allocated to the classes based upon the relative daily net assets of each class. Blue Chip Growth Portfolio–II Class pays Rule 12b-1 fees, in an amount not exceeding 0.25% of the class's average daily net assets.

Capital Transactions Each investor's interest in the net assets of the fund is represented by fund shares. The fund's net asset value (NAV) per share is computed at the close of the New York Stock Exchange (NYSE), normally 4 p.m. ET, each day the NYSE is open for business. However, the NAV per share may be calculated at a time other than the normal close of the NYSE if trading on the NYSE is restricted, if the NYSE closes earlier, or as may be permitted by the SEC. Purchases and redemptions of fund shares are transacted at the next-computed NAV per share, after receipt of the transaction order by T. Rowe Price Associates, Inc., or its agents.

New Accounting Guidance In June 2022, the FASB issued Accounting Standards Update (ASU), ASU 2022-03, Fair Value Measurement (Topic 820) – Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions, which clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments under this ASU are effective for fiscal years beginning after December 15, 2023; however, the fund opted to early adopt, as permitted, effective December 1, 2022. Adoption of the guidance did not have a material impact on the fund's financial statements.

The FASB issued Accounting Standards Update (ASU), ASU 2020–04, Reference Rate Reform (Topic 848) – Facilitation of the Effects of Reference Rate Reform on Financial Reporting in March 2020 and ASU 2021-01 in January 2021 which provided further amendments and clarifications to Topic 848. These ASUs provide optional, temporary relief with respect to the financial reporting of contracts subject to certain types of modifications due to the planned discontinuation of the London Interbank Offered Rate (LIBOR), and other interbank-offered based reference rates, through December 31, 2022. In December 2022, FASB issued ASU 2022-06 which defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024, after which entities will no longer be permitted to apply the relief in Topic 848. Management intends to rely upon the relief provided under Topic 848, which is not expected to have a material impact on the fund's financial statements.

Indemnification In the normal course of business, the fund may provide indemnification in connection with its officers and directors, service providers, and/or private company investments. The fund's maximum exposure under these arrangements is unknown; however, the risk of material loss is currently considered to be remote.

NOTE 2 - VALUATION

Fair Value The fund's financial instruments are valued at the close of the NYSE and are reported at fair value, which GAAP defines as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fund's Board of Directors (the Board) has designated T. Rowe Price Associates, Inc. as the fund's valuation designee (Valuation Designee). Subject to oversight by the Board, the Valuation Designee performs the following functions in performing fair value determinations: assesses and manages valuation risks; establishes and applies fair value methodologies; tests fair value methodologies; and evaluates pricing vendors and pricing agents. The duties and responsibilities of the Valuation Designee are performed by its Valuation Committee. The Valuation Designee provides periodic reporting to the Board on valuation matters.

Various valuation techniques and inputs are used to determine the fair value of financial instruments. GAAP establishes the following fair value hierarchy that categorizes the inputs used to measure fair value:

- Level 1 quoted prices (unadjusted) in active markets for identical financial instruments that the fund can access at the reporting date
- Level 2 inputs other than Level 1 quoted prices that are observable, either directly or indirectly (including, but not limited to, quoted prices for similar financial instruments in active markets, quoted prices for identical or similar financial instruments in inactive markets, interest rates and yield curves, implied volatilities, and credit spreads)
- Level 3 unobservable inputs (including the Valuation Designee's assumptions in determining fair value)

Observable inputs are developed using market data, such as publicly available information about actual events or transactions, and reflect the assumptions that market participants would use to price the financial instrument. Unobservable inputs are those for which market data are not available and are developed using the best information available about the assumptions that market participants would use to price the financial instrument. GAAP requires valuation techniques to maximize the use of relevant observable inputs and minimize the use of unobservable inputs. When multiple inputs are used to derive fair value, the financial instrument is assigned to the level within the fair value hierarchy based on the lowest-level input that is significant to the fair value of the financial instrument. Input levels are not necessarily an indication of the risk or liquidity associated with financial instruments at that level but rather the degree of judgment used in determining those values.

Valuation Techniques Equity securities, including exchange-traded funds, listed or regularly traded on a securities exchange or in the over-the-counter (OTC) market are valued at the last quoted sale price or, for certain markets, the official closing price at the time the valuations are made. OTC Bulletin Board securities are valued at the mean of the closing bid and asked prices. A security that is listed or traded on more than one exchange is valued at the quotation on the exchange determined to be the primary market for such security. Listed securities not traded on a particular day are valued at the mean of the closing bid and asked prices for domestic securities and the last quoted sale or closing price for international securities.

The last quoted prices of non-U.S. equity securities may be adjusted to reflect the fair value of such securities at the close of the NYSE, if the Valuation Designee determines that developments between the close of a foreign market and the close of the NYSE will affect the value of some or all of the fund's portfolio securities. Each business day, the Valuation Designee uses information from outside pricing services to evaluate the quoted prices of portfolio securities and, if appropriate, decide whether it is necessary to adjust quoted prices to reflect fair value by reviewing a variety of factors, including developments in foreign markets, the performance of U.S.

securities markets, and the performance of instruments trading in U.S. markets that represent foreign securities and baskets of foreign securities. The Valuation Designee uses outside pricing services to provide it with quoted prices and information to evaluate or adjust those prices. The Valuation Designee cannot predict how often it will use quoted prices and how often it will determine it necessary to adjust those prices to reflect fair value.

Debt securities generally are traded in the over-the-counter (OTC) market and are valued at prices furnished by independent pricing services or by broker dealers who make markets in such securities. When valuing securities, the independent pricing services consider factors such as, but not limited to, the yield or price of bonds of comparable quality, coupon, maturity, and type, as well as prices quoted by dealers who make markets in such securities.

Investments in mutual funds are valued at the mutual fund's closing NAV per share on the day of valuation. Assets and liabilities other than financial instruments, including short-term receivables and payables, are carried at cost, or estimated realizable value, if less, which approximates fair value.

Investments for which market quotations are not readily available or deemed unreliable are valued at fair value as determined in good faith by the Valuation Designee. The Valuation Designee has adopted methodologies for determining the fair value of investments for which market quotations are not readily available or deemed unreliable, including the use of other pricing sources. Factors used in determining fair value vary by type of investment and may include market or investment specific considerations. The Valuation Designee typically will afford greatest weight to actual prices in arm's length transactions, to the extent they represent orderly transactions between market participants, transaction information can be reliably obtained, and prices are deemed representative of fair value. However, the Valuation Designee may also consider other valuation methods such as market-based valuation multiples; a discount or premium from market value of a similar, freely traded security of the same issuer; discounted cash flows; yield to maturity; or some combination. Fair value determinations are reviewed on a regular basis. Because any fair value prices determined by the Valuation Designee could differ from those of other market participants, and it is possible that the fair value determined for a security may be materially different from the value that could be realized upon the sale of that security.

Valuation Inputs The following table summarizes the fund's financial instruments, based on the inputs used to determine their fair values on June 30, 2023 (for further detail by category, please refer to the accompanying Portfolio of Investments):

(\$000s)	Level 1	Level 2	Level 3	Total Value
Assets				
Common Stocks	\$ 1,825,805 \$	6,412 \$	2,843 \$	1,835,060
Convertible Preferred Stocks	_	_	3,983	3,983
Corporate Bonds	_	3,215	_	3,215
Short-Term Investments	7,234	_	_	7,234
Total	\$ 1,833,039 \$	9,627 \$	6,826 \$	1,849,492

NOTE 3 - OTHER INVESTMENT TRANSACTIONS

Consistent with its investment objective, the fund engages in the following practices to manage exposure to certain risks and/or to enhance performance. The investment objective, policies, program, and risk factors of the fund are described more fully in the fund's prospectus and Statement of Additional Information.

Restricted Securities The fund invests in securities that are subject to legal or contractual restrictions on resale. Prompt sale of such securities at an acceptable price may be difficult and may involve substantial delays and additional costs.

Securities Lending The fund may lend its securities to approved borrowers to earn additional income. Its securities lending activities are administered by a lending agent in accordance with a securities lending agreement. Security loans generally do not have stated maturity dates, and the fund may recall a security at any time. The fund receives collateral in the form of cash or U.S. government securities. Collateral is maintained over the life of the loan in an amount not less than the value of loaned securities; any additional

collateral required due to changes in security values is delivered to the fund the next business day. Cash collateral is invested in accordance with investment guidelines approved by fund management. Additionally, the lending agent indemnifies the fund against losses resulting from borrower default. Although risk is mitigated by the collateral and indemnification, the fund could experience a delay in recovering its securities and a possible loss of income or value if the borrower fails to return the securities, collateral investments decline in value, and the lending agent fails to perform. Securities lending revenue consists of earnings on invested collateral and borrowing fees, net of any rebates to the borrower, compensation to the lending agent, and other administrative costs. In accordance with GAAP, investments made with cash collateral are reflected in the accompanying financial statements, but collateral received in the form of securities is not. At June 30, 2023, there were no securities on loan.

Other Purchases and sales of portfolio securities other than short-term securities aggregated \$129,128,000 and \$287,055,000, respectively, for the six months ended June 30, 2023.

NOTE 4 - FEDERAL INCOME TAXES

Generally, no provision for federal income taxes is required since the fund intends to continue to qualify as a regulated investment company under Subchapter M of the Internal Revenue Code and distribute to shareholders all of its taxable income and gains. Distributions determined in accordance with federal income tax regulations may differ in amount or character from net investment income and realized gains for financial reporting purposes. Financial reporting records are adjusted for permanent book/tax differences to reflect tax character but are not adjusted for temporary differences. The amount and character of tax-basis distributions and composition of net assets are finalized at fiscal year-end; accordingly, tax-basis balances have not been determined as of the date of this report.

The fund intends to retain realized gains to the extent of available capital loss carryforwards. Net realized capital losses may be carried forward indefinitely to offset future realized capital gains. As of December 31, 2022, the fund had \$108,015,000 of available capital loss carryforwards.

At June 30, 2023, the cost of investments (including derivatives, if any) for federal income tax purposes was \$816,610,000. Net unrealized gain aggregated \$1,032,882,000 at period-end, of which \$1,082,415,000 related to appreciated investments and \$49,533,000 related to depreciated investments.

NOTE 5 - FOREIGN TAXES

The fund is subject to foreign income taxes imposed by certain countries in which it invests. Additionally, capital gains realized upon disposition of securities issued in or by certain foreign countries are subject to capital gains tax imposed by those countries. All taxes are computed in accordance with the applicable foreign tax law, and, to the extent permitted, capital losses are used to offset capital gains. Taxes attributable to income are accrued by the fund as a reduction of income. Current and deferred tax expense attributable to capital gains is reflected as a component of realized or change in unrealized gain/loss on securities in the accompanying financial statements. To the extent that the fund has country specific capital loss carryforwards, such carryforwards are applied against net unrealized gains when determining the deferred tax liability. Any deferred tax liability incurred by the fund is included in either Other liabilities or Deferred tax liability on the accompanying Statement of Assets and Liabilities.

NOTE 6 - RELATED PARTY TRANSACTIONS

The fund is managed by T. Rowe Price Associates, Inc. (Price Associates), a wholly owned subsidiary of T. Rowe Price Group, Inc. (Price Group). The investment management and administrative agreement between the fund and Price Associates provides for an all-inclusive annual fee equal to 0.85% of the fund's average daily net assets. The fee is computed daily and paid monthly. The all-inclusive fee covers investment management services and ordinary, recurring operating expenses but does not cover interest expense; expenses related to borrowing, taxes, and brokerage; or nonrecurring, extraordinary expenses. Effective July 1, 2018, Price Associates has contractually agreed, at least through April 30, 2024 to waive a portion of its management fee in order to limit the fund's management fee to 0.75% of the fund's average daily net assets. Thereafter, this agreement automatically renews for one-year terms unless terminated or modified by the fund's Board. Fees waived and expenses paid under this agreement are not subject to reimbursement to Price

Associates by the fund. The total management fees waived were \$823,000 and allocated ratably in the amounts of \$572,000 and \$251,000 for the Blue Chip Growth Portfolio Class and Blue Chip Growth Portfolio-II Class, respectively, for the six months ended June 30, 2023.

In addition, the fund has entered into service agreements with Price Associates and a wholly owned subsidiary of Price Associates, each an affiliate of the fund. Price Associates provides certain accounting and administrative services to the fund. T. Rowe Price Services, Inc. provides shareholder and administrative services in its capacity as the fund's transfer and dividend-disbursing agent. Pursuant to the all-inclusive fee arrangement under the investment management and administrative agreement, expenses incurred by the funds pursuant to these service agreements are paid by Price Associates.

The fund may invest its cash reserves in certain open-end management investment companies managed by Price Associates and considered affiliates of the fund: the T. Rowe Price Government Reserve Fund or the T. Rowe Price Treasury Reserve Fund, organized as money market funds (together, the Price Reserve Funds). The Price Reserve Funds are offered as short-term investment options to mutual funds, trusts, and other accounts managed by Price Associates or its affiliates and are not available for direct purchase by members of the public. Cash collateral from securities lending, if any, is invested in the T. Rowe Price Government Reserve Fund. The Price Reserve Funds pay no investment management fees.

The fund may participate in securities purchase and sale transactions with other funds or accounts advised by Price Associates (cross trades), in accordance with procedures adopted by the fund's Board and Securities and Exchange Commission rules, which require, among other things, that such purchase and sale cross trades be effected at the independent current market price of the security. During the six months ended June 30, 2023, the fund had no purchases or sales cross trades with other funds or accounts advised by Price Associates.

Price Associates has voluntarily agreed to reimburse the fund from its own resources on a monthly basis for the cost of investment research embedded in the cost of the fund's securities trades. This agreement may be rescinded at any time. For the six months ended June 30, 2023, this reimbursement amounted to \$9,000, which is included in Net realized gain (loss) on Securities in the Statement of Operations.

NOTE 7 - OTHER MATTERS

Unpredictable events such as environmental or natural disasters, war, terrorism, pandemics, outbreaks of infectious diseases, and similar public health threats may significantly affect the economy and the markets and issuers in which the fund invests. Certain events may cause instability across global markets, including reduced liquidity and disruptions in trading markets, while some events may affect certain geographic regions, countries, sectors, and industries more significantly than others, and exacerbate other pre-existing political, social, and economic risks.

Since 2020, a novel strain of coronavirus (COVID-19) has resulted in disruptions to global business activity and caused significant volatility and declines in global financial markets.

In February 2022, Russian forces entered Ukraine and commenced an armed conflict leading to economic sanctions being imposed on Russia and certain of its citizens, creating impacts on Russian-related stocks and debt and greater volatility in global markets.

In March 2023, the collapse of some US regional and global banks as well as overall concerns around the soundness and stability of the global banking sector has sparked concerns of a broader financial crisis impacting the overall global banking sector. In certain cases, government agencies have assumed control or otherwise intervened in the operations of certain banks due to liquidity and solvency concerns. The extent of impact of these events on the US and global markets is highly uncertain.

These are recent examples of global events which may have a negative impact on the values of certain portfolio holdings or the fund's overall performance. Management is actively monitoring the risks and financial impacts arising from these events.

INFORMATION ON PROXY VOTING POLICIES, PROCEDURES, AND RECORDS

A description of the policies and procedures used by T. Rowe Price funds to determine how to vote proxies relating to portfolio securities is available in each fund's Statement of Additional Information. You may request this document by calling 1-800-225-5132 or by accessing the SEC's website, sec.gov.

The description of our proxy voting policies and procedures is also available on our corporate website. To access it, please visit the following Web page:

https://www.troweprice.com/corporate/us/en/utility/policies.html

Scroll down to the section near the bottom of the page that says, "Proxy Voting Guidelines." Click on the links in the shaded box.

Each fund's most recent annual proxy voting record is available on our website and through the SEC's website. To access it through T. Rowe Price, visit the website location shown above, and scroll down to the section near the bottom of the page that says, "Proxy Voting Records." Click on the Proxy Voting Records link in the shaded box.

RESULTS OF PROXY VOTING

A Special Meeting of Shareholders was held on July 24, 2023 for shareholders of record on April 7, 2023, to elect the following directornominees to serve on the Board of all Price Funds. The newly elected Directors took office effective July 24, 2023.

The results of the voting were as follows:

	Votes For	Votes Withheld
Melody Bianchetto	74,096,003	4,864,479
Mark J. Parrell	76,629,190	2,346,625
Kellye L. Walker	76,708,663	2,268,629
Eric L. Veiel	76,898,359	2,090,473

Teresa Bryce Bazemore, Bruce W. Duncan, Robert J. Gerrard, Jr., Paul F. McBride and David Oestreicher continue to serve as Directors on the Board of all Price Funds.

HOW TO OBTAIN QUARTERLY PORTFOLIO HOLDINGS

The fund files a complete schedule of portfolio holdings with the Securities and Exchange Commission (SEC) for the first and third quarters of each fiscal year as an exhibit to its reports on Form N-PORT. The fund's reports on Form N-PORT are available electronically on the SEC's website (sec.gov). In addition, most T. Rowe Price funds disclose their first and third fiscal quarter-end holdings on **troweprice.com**.

APPROVAL OF INVESTMENT MANAGEMENT AGREEMENT

Each year, the fund's Board of Directors (Board) considers the continuation of the investment management agreement (Advisory Contract) between the fund and its investment adviser, T. Rowe Price Associates, Inc. (Adviser). In that regard, at a meeting held on March 6–7, 2023 (Meeting), the Board, including all of the fund's independent directors, approved the continuation of the fund's Advisory Contract. At the Meeting, the Board considered the factors and reached the conclusions described below relating to the selection of the Adviser and the approval of the Advisory Contract. The independent directors were assisted in their evaluation of the Advisory Contract by independent legal counsel from whom they received separate legal advice and with whom they met separately.

In providing information to the Board, the Adviser was guided by a detailed set of requests for information submitted by independent legal counsel on behalf of the independent directors. In considering and approving the continuation of the Advisory Contract, the Board considered the information it believed was relevant, including, but not limited to, the information discussed below. The Board considered not only the specific information presented in connection with the Meeting but also the knowledge gained over time through interaction with the Adviser about various topics. The Board meets regularly and, at each of its meetings, covers an extensive agenda of topics and materials and considers factors that are relevant to its annual consideration of the renewal of the T. Rowe Price funds' advisory contracts, including performance and the services and support provided to the funds and their shareholders.

Services Provided by the Adviser

The Board considered the nature, quality, and extent of the services provided to the fund by the Adviser. These services included, but were not limited to, directing the fund's investments in accordance with its investment program and the overall management of the fund's portfolio, as well as a variety of related activities such as financial, investment operations, and administrative services; compliance; maintaining the fund's records and registrations; and shareholder communications. The Board also reviewed the background and experience of the Adviser's senior management team and investment personnel involved in the management of the fund, as well as the Adviser's compliance record. The Board concluded that the information it considered with respect to the nature, quality, and extent of the services provided by the Adviser, as well as the other factors considered at the Meeting, supported the Board's approval of the continuation of the Advisory Contract.

Investment Performance of the Fund

The Board took into account discussions with the Adviser and detailed reports that it regularly receives throughout the year on relative and absolute performance for the T. Rowe Price funds. In connection with the Meeting, the Board reviewed information provided by the Adviser that compared the fund's total returns, as well as a wide variety of other previously agreed-upon performance measures and market data, against relevant benchmark indexes and peer groups of funds with similar investment programs for various periods through December 31, 2022. Additionally, the Board reviewed the fund's relative performance information as of September 30, 2022, which ranked the returns of the fund's Investor Class for various periods against a universe of funds with similar investment programs selected by Broadridge, an independent provider of mutual fund data.

In the course of its deliberations, the Board considered performance information provided throughout the year and in connection with the Advisory Contract review at the Meeting, as well as information provided during investment review meetings conducted with portfolio managers and senior investment personnel during the course of the year regarding the fund's performance. The Board also considered relevant factors, such as overall market conditions and trends that could adversely impact the fund's performance, length of the fund's performance track record, and how closely the fund's strategies align with its benchmarks and peer groups. The Board noted that, as of December 31, 2022, the fund lagged its benchmark for most performance periods and the fund's total returns ranked in the fourth quartile for most periods when compared with performance peer groups selected by third-party data providers. The Adviser provided the Board with information addressing the fund's performance relative to its benchmarks and performance peers during the applicable periods, the primary reasons for such results, and efforts being undertaken to improve performance. The Board considered the Adviser's responses and its efforts and plans to improve the fund's investment performance and noted that it will continue to periodically review the fund's performance. The Board occurs and noted that the information it considered with respect to the fund's performance, as well as the other factors considered at the Meeting, supported the Board's approval of the continuation of the Advisory Contract.

APPROVAL OF INVESTMENT MANAGEMENT AGREEMENT (CONTINUED)

Costs, Benefits, Profits, and Economies of Scale

The Board reviewed detailed information regarding the revenues received by the Adviser under the Advisory Contract and other direct and indirect benefits that the Adviser (and its affiliates) may have realized from its relationship with the fund. In considering soft-dollar arrangements pursuant to which research may be received from broker-dealers that execute the fund's portfolio transactions, the Board noted that the Adviser bears the cost of research services for all client accounts that it advises, including the T. Rowe Price funds. The Board received information on the estimated costs incurred and profits realized by the Adviser from managing the T. Rowe Price funds. The Board also reviewed estimates of the profits realized from managing the fund in particular, and the Board concluded that the Adviser's profits were reasonable in light of the services provided to the fund.

The Board also considered whether the fund benefits under the fee levels set forth in the Advisory Contract or otherwise from any economies of scale realized by the Adviser. Under the Advisory Contract, the fund pays the Adviser an all-inclusive management fee, which is based on the fund's average daily net assets. The all-inclusive management fee includes investment management services and provides for the Adviser to pay all of the fund's ordinary, recurring operating expenses except for interest, taxes, portfolio transaction fees, and any nonrecurring extraordinary expenses that may arise. However, the fund has a contractual limitation in place whereby the Adviser has agreed to waive a portion of the management fee it is entitled to receive from the fund in order to limit the fund's overall management fee rate to 0.75% of the fund's average daily net assets. Any fees waived under this management fee waiver agreement are not subject to reimbursement to the Adviser by the fund. The Adviser has generally implemented an all-inclusive management fee structure in situations where a fixed total expense ratio is useful for purposes of providing certainty of fees and expenses for the fund's investors and has historically sought to set the initial all-inclusive management fee rate at levels below the expense ratios of comparable funds to take into account potential future economies of scale. Because the fund serves as an underlying option to variable annuity products, the all-inclusive fee structure is utilized to create certainty for the annuity providers' overall pricing decisions and disclosures. In addition, the assets of the fund are included in the calculation of the group fee rate, which serves as a component of the management fee for many T. Rowe Price funds and declines at certain asset levels based on the combined average net assets of most of the T. Rowe Price funds (including the fund). Although the fund does not have a group fee component to its management fee, its assets are included in the calculation because certain resources utilized to operate the fund are shared with other T. Rowe Price funds.

In addition, the Board noted that the fund potentially shares in indirect economies of scale through the Adviser's ongoing investments in its business in support of the T. Rowe Price funds, including investments in trading systems, technology, and regulatory support enhancements, and the ability to possibly negotiate lower fee arrangements with third-party service providers. The Board concluded that the advisory fee structure for the fund provides for a reasonable sharing of benefits from any economies of scale with the fund's investors.

Fees and Expenses

The Board was provided with information regarding industry trends in management fees and expenses. Among other things, the Board reviewed data for peer groups that were compiled by Broadridge, which compared: (i) contractual management fees, actual management fees, nonmanagement expenses, and total expenses of the fund with a group of competitor funds selected by Broadridge (Expense Group) and (ii) actual management fees, nonmanagement expenses, and total expenses of the fund with a broader set of funds within the Lipper investment classification (Expense Universe). The Board considered the fund's contractual management fee rate, actual management fee rate (which reflects the fund's all-inclusive management fee rate reduced by the fund's management fee waiver arrangement), and total expenses (which reflect the fund's all-inclusive management fee rate reduced by the fund's management fee waiver arrangement) in comparison with the information for the Broadridge peer groups. Broadridge generally constructed the peer groups by seeking the most comparable funds based on similar investment classifications and objectives, expense structure, asset size, and operating components and attributes and ranked funds into quintiles, with the first quintile representing the funds with the lowest relative expenses and the fifth quintile representing the funds with the highest relative expenses. The information provided to the Board indicated that the fund's contractual management fee ranked in the fifth quintile (Expense Group), the fund's actual management fee rate ranked in the fifth quintile (Expense Group), and Expense Universe).

The Adviser provided the Board with additional information with respect to the fund's relative management fees and total expenses ranking in the fifth quintile. The Board reviewed and considered the information provided relating to the fund, including other funds in the peer group, and other factors that the Board determined to be relevant.

APPROVAL OF INVESTMENT MANAGEMENT AGREEMENT (CONTINUED)

The Board also reviewed the fee schedules for other investment portfolios with similar mandates that are advised or subadvised by the Adviser and its affiliates, including separately managed accounts for institutional and individual investors; subadvised funds; and other sponsored investment portfolios, including collective investment trusts and pooled vehicles organized and offered to investors outside the United States. Management provided the Board with information about the Adviser's responsibilities and services provided to subadvisory and other institutional account clients, including information about how the requirements and economics of the institutional business are fundamentally different from those of the proprietary mutual fund business. The Board considered information about business and considered various relevant factors, such as the broader scope of operations and oversight, more extensive shareholder communication infrastructure, greater asset flows, heightened business risks, and differences in applicable laws and regulations associated with the Adviser's proprietary mutual fund business. In assessing the reasonableness of the fund's management fee rate, the Board considered the differences in the nature of the services required for the Adviser to manage its mutual fund business versus managing a discrete pool of assets as a subadviser to another institution's mutual fund or for an institutional account and that the Adviser generally performs significant additional services and assumes greater risk in managing the fund and other T. Rowe Price funds than it does for institutional account clients, including subadvised funds.

On the basis of the information provided and the factors considered, the Board concluded that the fees paid by the fund under the Advisory Contract are reasonable.

Approval of the Advisory Contract

As noted, the Board approved the continuation of the Advisory Contract. No single factor was considered in isolation or to be determinative to the decision. Rather, the Board concluded, in light of a weighting and balancing of all factors considered, that it was in the best interests of the fund and its shareholders for the Board to approve the continuation of the Advisory Contract (including the fees to be charged for services thereunder).

T.RowePrice®

100 East Pratt Street Baltimore, MD 21202

Call 1-800-225-5132 to request a prospectus or summary prospectus; each includes investment objectives, risks, fees, expenses, and other information that you should read and consider carefully before investing.

T. Rowe Price Investment Services, Inc.